Literature DB >> 16917004

Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition.

Nicola Giuliani1, Vittorio Rizzoli, G David Roodman.   

Abstract

Multiple myeloma (MM) is a plasma cell malignancy characterized by a high capacity to induce osteolytic bone lesions. Bone destruction in MM results from increased osteoclast formation and activity that occur in close proximity to myeloma cells. However, histomorphometric studies have demonstrated that MM patients with osteolytic bone lesions have lower numbers of osteoblasts and decreased bone formation. This impaired bone formation plays a critical role in the bone-destructive process. Recently, the biologic mechanisms involved in the osteoblast inhibition induced by MM cells have begun to be elucidated. In this article, the pathophysiology underlying osteoblast inhibition in MM is reviewed.

Entities:  

Mesh:

Year:  2006        PMID: 16917004     DOI: 10.1182/blood-2006-05-026112

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  96 in total

Review 1.  Proteasome inhibitors and bone disease.

Authors:  Ya-Wei Qiang; Christoph J Heuck; John D Shaughnessy; Bart Barlogie; Joshua Epstein
Journal:  Semin Hematol       Date:  2012-07       Impact factor: 3.851

Review 2.  Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma.

Authors:  Masahiro Abe
Journal:  Int J Hematol       Date:  2011-10-18       Impact factor: 2.490

3.  The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells.

Authors:  Simona Colla; Fenghuang Zhan; Wei Xiong; Xiaosong Wu; Hongwei Xu; Owen Stephens; Shmuel Yaccoby; Joshua Epstein; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2007-01-25       Impact factor: 22.113

4.  CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone disease.

Authors:  Sarah K Johnson; James P Stewart; Rakesh Bam; Pingping Qu; Bart Barlogie; Frits van Rhee; John D Shaughnessy; Joshua Epstein; Shmuel Yaccoby
Journal:  Blood       Date:  2014-07-24       Impact factor: 22.113

5.  Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma.

Authors:  Michelle M McDonald; Michaela R Reagan; Scott E Youlten; Sindhu T Mohanty; Anja Seckinger; Rachael L Terry; Jessica A Pettitt; Marija K Simic; Tegan L Cheng; Alyson Morse; Lawrence M T Le; David Abi-Hanna; Ina Kramer; Carolyne Falank; Heather Fairfield; Irene M Ghobrial; Paul A Baldock; David G Little; Michaela Kneissel; Karin Vanderkerken; J H Duncan Bassett; Graham R Williams; Babatunde O Oyajobi; Dirk Hose; Tri G Phan; Peter I Croucher
Journal:  Blood       Date:  2017-05-17       Impact factor: 22.113

Review 6.  Effects on bone metabolism of new therapeutic strategies with standard chemotherapy and biologic drugs.

Authors:  Stefania Ciolli
Journal:  Clin Cases Miner Bone Metab       Date:  2013-09

7.  The roles of Wnt signaling modulators Dickkopf-1 (Dkk1) and Dickkopf-2 (Dkk2) and cell maturation state in osteogenesis on microstructured titanium surfaces.

Authors:  Rene Olivares-Navarrete; Sharon Hyzy; Marco Wieland; Barbara D Boyan; Zvi Schwartz
Journal:  Biomaterials       Date:  2009-12-09       Impact factor: 12.479

8.  IL-7 suppresses osteogenic differentiation of periodontal ligament stem cells through inactivation of mitogen-activated protein kinase pathway.

Authors:  Cong-Xiang Jian; Quan-Shui Fan; Yong-He Hu; Yong He; Ming-Zhe Li; Wei-Yin Zheng; Yu Ren; Chen-Jun Li
Journal:  Organogenesis       Date:  2016-08-31       Impact factor: 2.500

9.  In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma.

Authors:  Enrique M Ocio; David Vilanova; Peter Atadja; Patricia Maiso; Edvan Crusoe; Diego Fernández-Lázaro; Mercedes Garayoa; Laura San-Segundo; Teresa Hernández-Iglesias; Enrique de Alava; Wenlin Shao; Yung-Mae Yao; Atanasio Pandiella; Jesús F San-Miguel
Journal:  Haematologica       Date:  2009-11-30       Impact factor: 9.941

10.  Combination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-κB activity.

Authors:  Kelley Salem; Charles O Brown; Jeanine Schibler; Apollina Goel
Journal:  Exp Hematol       Date:  2012-10-11       Impact factor: 3.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.